Annogen
Company Details
Status: Private
Employees: 11-50
Location:
Amsterdam, Netherlands
Type:
sample
Technology:
sample
sample
About: Bespoke promoters and enhancers, for any tissue, any organism.
At Annogen, our vision is a future where safe and effective advanced therapies are specifically expressed in the right tissues with no off-target effects. We believe that this can be achieved by bespoke promoters (genetic switches) and genomic expression sites.
Therefore, Annogen is on a mission towards becoming the leading expertise center for gene expression engineering in order to improve the safety and effectiveness of tomorrow's cell and gene therapies.
Annogen leverages its proprietary SuRE™ technology to identify regulatory DNA elements to be used for controlled (therapeutic) gene expression for gene & cell therapy, as well as for recombinant protein and virus production. In addition, we develop service projects based on our proprietary AIM™ technology to identify favorable gene insertions and their expression levels for more than 100,000 integrations in parallel. These approaches typically enable big improvements in any biomedical strategy involving the (over-) expression of genes.
Annogen was founded in 2017 by Dr. Joris van Arensbergen, who developed and published the SuRE™ technology as a post-doctoral fellow in the laboratory of Prof. Dr. Bas van Steensel at the world-renowned Netherlands Cancer Institute (NKI). Today, Annogen is the trusted partner for bespoke gene expression engineering for leading biopharmaceutical, agricultural and academic research centers globally.
Unlock access to company contacts, hot leads, and drug pipelines.
Log in or create a free account now!
Annogen | Active clinical trials on ClinicalTrials.gov
Active Clinical Trials Count | 0
No Active Trials Found On ClinicalTrials.gov.